Bruker stock performance snapshot
Bruker (BRKR) has drawn attention after recent trading, with the share price at about $36.76. The stock shows a 1.9% gain over the past day and 7.1% over the past week.
Looking a bit further back, Bruker is roughly flat over the past month and has a 30.2% decline over the past 3 months. Year to date, the stock shows a 23.6% decline, with a 4.5% decline over the past year.
Over longer horizons, Bruker’s 3 year total return reflects a 53% decline, while the 5 year total return shows a 44.7% decline. These figures provide context for assessing how current fundamentals relate to past shareholder outcomes.
See our latest analysis for Bruker.
The recent 7 day share price return of 7.1% comes after a year in which total shareholder return declined 4.5%, and the 3 year total shareholder return declined 53%, so recent momentum follows a longer period of weaker outcomes.
If Bruker’s moves have you reassessing where you put fresh capital, this can be a good moment to broaden your watchlist and uncover 20 top founder-led companies
With the share price under pressure over the past year but recent returns turning positive, and with analyst targets sitting above the current US$36.76 level, the key question is whether there is a buying opportunity here or if the market is already pricing in future growth.
Most Popular Narrative: 23.2% Undervalued
Bruker’s most followed narrative pegs fair value at about $47.86 per share, versus the last close of $36.76, and builds a case around future earnings power under an 8.65% discount rate.
The expected stabilization and eventual recovery of research and biopharma funding in both the US and China, along with global settlements on tariffs, could trigger a rebound in demand for Bruker's advanced life science and drug discovery instruments, supporting renewed top-line revenue growth post-2025.
Want to see what sits behind that optimism on funding, margins and earnings? The narrative leans on a detailed path for revenue, profitability and the future profit multiple applied to those earnings.
Result: Fair Value of $47.86 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story still hinges on research funding not staying weak for too long and on Bruker delivering its planned cost savings without demand slipping further.
Find out about the key risks to this Bruker narrative.
Another View: Cash Flows Paint A Tighter Picture
While the analyst narrative sees Bruker as about 23% undervalued at $47.86 per share, the Simply Wall St DCF model is more cautious and puts future cash flow value closer to $35.78. With the stock at $36.76, that points to a mild premium rather than a clear discount.
For a closer look at how those cash flow assumptions stack up against the narrative and price target, Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Bruker for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages across narratives and valuation models can be a useful signal to look closer rather than sit on the fence. Take a moment to review the numbers, understand both the red flags and potential upsides, and weigh them against your own expectations with the help of the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If Bruker has sharpened your focus, do not stop here. Use this momentum to scan wider, compare alternatives and keep your capital working on your terms.
- Target resilient balance sheets and clear fundamentals with the solid balance sheet and fundamentals stocks screener (40 results).
- Hunt for quality companies that trade below estimated worth using the 58 high quality undervalued stocks.
- Spot potential future standouts before the crowd by checking the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com